Effect of PPARγ ligands on the viability of gastric epithelial cells

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 16, Issue 2, 2002, Pages 67-73

  Kojima, K ^a   Shimada, T ^a   Mitobe, Y ^a   Yoshiura, K ^a   Hiraishi, H ^a   Terano, A ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; CELL RECEPTOR; CHROMAN DERIVATIVE; COMPLEMENTARY DNA; DRUG DERIVATIVE; LIGAND; PROSTAGLANDIN D2; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GROWTH REGULATION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH EPITHELIUM; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHASE CONTRAST MICROSCOPY; STOMACH MUCOSA;

ANIMALS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; BLOTTING, WESTERN; CELL SURVIVAL; CHROMANS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; GASTRIC MUCOSA; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MICROSCOPY, PHASE-CONTRAST; PROSTAGLANDIN D2; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036550703     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-8.
2. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000; 40: 491-518.
3. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid- activated transcription factor. Cell 1994; 79: 1147-56.
4. Tontonoz P, Hu E, Graves RA, et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-34.
5. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996; 12: 335-63.
6. Mandrup S, Lane MD, Regulating adipogenesis. J Biol Chem 1997; 272: 5367-70.
7. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-12.
8. Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83: 813-19.
9. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
10. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-89.
11. Mansen A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996; 222: 844-51.
12. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
13. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
14. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-7.
15. Takahashi N, Okumura T, Motomura W, et al. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-9.
16. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000; 83: 1394-400.
17. Terano A, Ivey KJ, Stachura J, et al. Cell culture of rat gastric fundic mucosa. Gastroenterology 1982; 83: 1280-91.
18. Keelan JA, Sato TA, Marvin KW, et al. 15-Deoxy-Delta (12, 14)-prostaglandin J (2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 1999; 262: 579-585.
19. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activatcd receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-11.
20. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999; 274: 17042-8.
21. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-80.
22. Lim H, Gupta RA, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999; 13: 1561-74.
23. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804.
24. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10.